Standout Papers

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with i... 2013 2026 2017 2021 925
  1. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial (2013)
    Mathias Rummel, N. Niederle et al. The Lancet

Immediate Impact

5 by Nobel laureates 34 from Science/Nature 53 standout
Sub-graph 1 of 21

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Naturally occurring T cell mutations enhance engineered T cell therapies
2024 StandoutNature
2 intermediate papers

Works of Eckhart Weidmann being referenced

ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 Trials
2013
Epstein–Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma
2008

Author Peers

Author Last Decade Papers Cites
Eckhart Weidmann 2062 1283 1362 1930 111 4.9k
Ivor Royston 1717 2157 1107 1836 99 5.5k
Antonio Pinto 2230 1582 1257 2152 234 5.4k
Hartmut Kirchner 1712 1172 1330 1924 117 4.9k
David M. Dorfman 1616 2416 1585 1791 153 6.6k
Lisa M. Rimsza 3417 1225 1340 2577 198 6.0k
Javier Briones 1304 1655 816 1818 160 4.4k
Pierluigi Porcu 2607 2138 1737 2543 283 6.8k
Felipe Samaniego 3069 1177 2118 3126 217 7.2k
Xavier Mariette 1361 1358 1014 1186 69 7.3k
G. Verhoef 1367 539 934 1439 103 4.4k

All Works

Loading papers...

Rankless by CCL
2026